Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.33.

A number of analysts have commented on the company. Stifel Nicolaus began coverage on Whitehawk Therapeutics in a report on Wednesday, September 30th. They set a “buy” rating and a $9.00 price objective for the company. B. Riley Financial started coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They issued a “buy” rating and a $10.00 target price on the stock. Leerink Partners assumed coverage on Whitehawk Therapeutics in a report on Monday, July 13th. They set an “outperform” rating and a $9.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Wednesday, September 2nd. Finally, Wall Street Zen upgraded shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th.

Whitehawk Therapeutics Price Performance

NASDAQ:WHWK opened at $2.97 on Thursday. The firm has a 50-day moving average of $4.22 and a 200-day moving average of $4.12. Whitehawk Therapeutics has a one year low of $1.97 and a one year high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.10. As a group, sell-side analysts expect that Whitehawk Therapeutics will post -1.07 EPS for the current year.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of institutional investors have recently added to or reduced their stakes in WHWK. Two Sigma Securities LLC bought a new position in shares of Whitehawk Therapeutics in the second quarter valued at approximately $46,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Whitehawk Therapeutics during the first quarter valued at approximately $40,000. Deutsche Bank AG purchased a new stake in shares of Whitehawk Therapeutics during the second quarter valued at approximately $145,000. Bank of America Corp DE bought a new stake in Whitehawk Therapeutics during the second quarter worth $159,000. Finally, Seven Fleet Capital Management LP bought a new stake in Whitehawk Therapeutics during the first quarter worth $187,000. 52.08% of the stock is owned by institutional investors.

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s work centers on precision medicines intended to selectively target diseased cells while limiting damage to healthy tissue.

Whitehawk Therapeutics is advancing a pipeline of investigational therapeutic programs, with development activities focused primarily on oncology. As a clinical-stage company, its product candidates remain subject to preclinical and clinical testing, as well as review by applicable regulatory authorities, before any potential commercialization.

Publicly available information about the company’s specific pipeline, geographic operations, and leadership is limited.